Vaccines: Technological Platforms, Mission Indradhanush & eVIN Logistics

1. VACCINE PLATFORMS: mRNA, VECTOR, INACTIVATED & DNA

Cue Words	Notes
Genetic & Vector-Based Platforms	**mRNA (e.g., Pfizer/Moderna)**: Delivers a synthetic messenger RNA sequence instructing host cells to manufacture the pathogen's spike protein, triggering an antibody response; requires ultra-cold storage. **Viral Vector (e.g., Covishield/Sputnik)**: Uses a modified, non-replicating adenovirus to carry the pathogen's target-protein genetic blueprint into cells. **Plasmid DNA (e.g., ZyCoV-D)**: India's world-first human DNA vaccine, delivering an engineered DNA plasmid into skin cells via a needle-free applicator, transcribed to produce target antigens.
Conventional & Mucosal Platforms	**Inactivated (e.g., Covaxin)**: Uses a chemically killed pathogen that cannot replicate but still displays antigens to activate the immune system. **Intranasal Mucosal (e.g., iNCOVACC)**: A needle-free nasal spray stimulating localized IgA mucosal antibodies in the upper respiratory tract to block transmission routes at the point of entry.

> **Summary**: India's vaccine platform base spans the full technological spectrum — from cold-chain-intensive mRNA to India-pioneered plasmid DNA (ZyCoV-D) and transmission-blocking mucosal delivery (iNCOVACC) — giving domestic manufacturers flexibility across disease targets and logistics constraints.

2. UNIVERSAL IMMUNIZATION PROGRAMME, MISSION INDRADHANUSH & CERVAVAC

Cue Words	Notes
Universal Immunization Programme (UIP)	Provides free vaccination against 12 diseases: TB, Diphtheria, Pertussis, Tetanus, Polio, Hepatitis B, Pneumonia, Meningitis, Measles, Rubella, Japanese Encephalitis, and Rotavirus.
Mission Indradhanush: Closing Coverage Gaps	A targeted drive focused on low-coverage districts, immunizing 5.46 Crore children and 1.32 Crore pregnant women, raising full immunization coverage to 93.8% in targeted districts.
CERVAVAC & the 2026 National HPV Rollout	Indigenously developed quadrivalent HPV vaccine (targeting strains 6, 11, 16, 18) addressing India's cervical cancer burden (~75,000 deaths annually, roughly one every 7 minutes) at ₹200-400/dose versus ₹3,000+ for imported alternatives. 2026 marked India's first nationwide HPV immunisation campaign, rolling out CERVAVAC free to the 9-14 age cohort (targeting ~7 crore girls) through schools (Class 5-9) and health sub-centres, with a phased state-by-state expansion.

> **Summary**: UIP's 12-disease umbrella and Mission Indradhanush's district-targeting have pushed routine coverage above 93%, while 2026's nationwide CERVAVAC rollout extends this model to cancer prevention — turning a domestically developed, low-cost HPV vaccine into a school-delivered public health programme.

2A. NATIONWIDE HPV VACCINATION CAMPAIGN LAUNCH (28 FEB 2026) 2026

Cue Words	Notes
Launch details and vaccine used	PM Narendra Modi launched a nationwide HPV Vaccination Campaign for 14-year-old girls on 28 Feb 2026, from Ajmer, Rajasthan. Vaccine used: Gardasil-4 (quadrivalent, covers HPV types 6, 11, 16, 18); administered as a single dose, free of cost, voluntary with parental/guardian consent recorded via the U-WIN digital platform. Campaign runs in campaign-mode for 3 months, after which HPV vaccination folds into routine immunization.
Burden and targets	Cervical cancer is the 2nd most common cancer among Indian women — ~1.2 lakh new cases and ~80,000 deaths annually (WHO GLOBOCAN 2022). Target: ~1.2 crore girls per year (cohort estimate per Registrar General of India 2021 data). Globally, 160 of 194 countries have introduced HPV vaccine in national immunization programmes; 90 countries use a single-dose schedule.

> **Summary**: The 28 Feb 2026 Ajmer launch operationalises India's HPV drive at national scale using the imported Gardasil-4 (distinct from the indigenous CERVAVAC track), targeting 14-year-olds specifically and consent-tracked via U-WIN — aligning India with the majority of countries that have already adopted single-dose national HPV immunization.

2B. INDIA'S FIRST DENGUE VACCINE APPROVAL (21 JULY 2026) 2026

Cue Words	Notes
Approval and vaccine profile	**CDSCO** (Central Drugs Standard Control Organisation) approved India's **first-ever dengue vaccine** — **Qdenga®** (Dengue Tetravalent Vaccine, Live Attenuated) — on **21 July 2026**. Manufactured by **Takeda GmbH** (Germany); imported by **Takeda Biopharmaceuticals India**. Uses **recombinant DNA technology**, produced in **Vero cells**, built on a **dengue virus type-2 backbone** with genes from other serotypes; contains **GMOs**. Administered as a **subcutaneous injection**, **2 doses (0.5 ml each)**, **3 months apart**; indicated for ages **4-60**.
Global adoption and Indian context	Already approved in 42 countries (including the EU, UK, Switzerland) and holds WHO prequalification; more than 24 million doses distributed globally. Complements India's existing National Vector Borne Disease Control Programme.

> **Summary**: Qdenga's 21 July 2026 CDSCO approval gives India its first dengue vaccine, using a recombinant live-attenuated Vero-cell platform already validated in 42 countries with WHO prequalification — a complement, not replacement, for India's vector-control-led dengue strategy.

3. COLD-CHAIN LOGISTICS (eVIN) & VACCINE DIPLOMACY

Cue Words	Notes
eVIN: Electronic Vaccine Intelligence Network	A digital platform tracking vaccine logistics in real time across 29,000+ cold-chain points. Uses IoT-enabled temperature loggers inside vaccine refrigerators to send instant SMS alerts on temperature drops, preventing stock wastage — the logistics backbone that makes programmes like the CERVAVAC rollout deliverable at scale.
Global Manufacturing Scale & Vaccine Maitri	India manufactures **~60% of all vaccines supplied globally**, serving as the chief supplier for UNICEF, GAVI, and PAHO. **Vaccine Maitri**: Soft-power diplomacy initiative exporting domestically manufactured vaccines to neighbouring and Global South countries, leveraging this manufacturing scale for foreign-policy goodwill.

> **Summary**: eVIN's real-time cold-chain monitoring underpins India's ability to deliver both domestic programmes and export commitments, while the country's ~60% share of global vaccine supply gives Vaccine Maitri its diplomatic weight.

UPSC Mains PYQs

• Vaccine Diplomacy & Technologies: Explain the different technological platforms used in developing COVID-19 vaccines. Evaluate the role of India's 'Vaccine Maitri' initiative in providing affordable immunization access to the Global South. (15 Marks, 250 Words)

• Active vs passive immunisation: active immunisation gives an antigen (killed/attenuated organism, subunit, toxoid, or mRNA/vector vaccine), prompting the body to produce its own antibodies and memory cells -- slow onset (days-weeks) but long-lasting (months-years), often needing boosters. Passive immunisation gives ready-made antibodies (immunoglobulin/antiserum/monoclonal antibodies) for immediate but short-lived protection (weeks to a few months) with no memory cells, used for post-exposure or rapid protection.
• Active vaccination examples include BCG, DPT, MMR, Hepatitis B, and COVID-19 vaccines (used for prevention before exposure); passive immunisation examples include rabies immunoglobulin, tetanus immunoglobulin, Hepatitis B immunoglobulin, anti-snake venom, and monoclonal antibodies (used post-exposure or when rapid protection is needed).
• An Adverse Event Following Immunisation (AEFI) is any untoward medical occurrence after immunisation that does not necessarily have a causal relationship to the vaccine; AEFIs are classified as vaccine product-related reactions, vaccine quality-related reactions, immunisation error-related reactions, immunisation anxiety-related reactions, and coincidental events.
• There are three broad approaches to vaccine design: using a whole (attenuated/inactivated) virus or bacterium, using antigenic parts of the pathogen that trigger the immune system (subunit/toxoid/conjugate), or using just the pathogen's genetic material (nucleic acid/mRNA/DNA vaccines); vaccines can also be classified by administration route -- intramuscular, intravenous, subcutaneous, nasal, oral.
• Inactivated vaccines use a killed version of the disease-causing germ and are used for Hepatitis A, influenza (injectable/shot form), polio (injectable/IPV form), and rabies.
• Live attenuated vaccines (used for Measles, Mumps, Rubella) generate strong, long-lasting immunity without needing booster shots (fewer doses required), but have the limitation that they can cause disease in people with a compromised immune system and need to be kept cool, creating cold-chain transport challenges.
• Subunit vaccines use purified, antigenic parts of a pathogen (proteins, peptides, or polysaccharides) rather than the whole organism, so they carry no risk of causing disease and suit immunocompromised individuals; limitations include being complex to manufacture, requiring adjuvants and booster shots, and needing time to identify which antigenic combination works best.
• Recombinant vector vaccines use recombinant DNA technology to engineer a safe virus/bacterium (e.g. an adenovirus, measles virus, or influenza virus vector) to deliver a specific sub-part of the target pathogen into cells, triggering an immune response without causing the actual disease.
• Conjugate vaccines are a type of subunit vaccine in which a weak polysaccharide antigen is covalently attached to a strong protein antigen -- used in bacterial vaccines targeting pathogens with polysaccharide capsules, e.g. the Pneumococcal vaccine -- to provide long-lasting immunity even in infants and young children whose immune response to polysaccharide alone is weak.
• Polysaccharide vaccines consist of a polysaccharide (carbohydrate) molecule rather than protein, which is unusual since vaccines are generally protein-based; this is the basis for the polysaccharide component in conjugate vaccine design.
• Nucleic acid vaccines use genetic material from a pathogen and include DNA vaccines and RNA (mRNA) vaccines; mRNA vaccines do not enter the cell nucleus, unlike viral vector (DNA-based) vaccines, and offer very fast development speed with a high safety profile.
• Self-amplifying mRNA (saRNA) vaccines represent a next-generation platform: the mRNA codes for additional (replicase) proteins that enable amplification of the mRNA strand inside the cell, mass-producing antigen 'blueprints' and triggering a strong immune response with a smaller initial dose. Developed by Arcturus Therapeutics Holdings (US), saRNA vaccines have shown promising results against COVID-19.
• DNA vaccines deliver a plasmid coding for the antigen, inserted intramuscularly and driven into cells using electroporation; benefits include not requiring ultra-cold storage (unlike mRNA vaccines) and being cost-effective to produce.
• Among India's COVID-19 vaccines, Covishield (developed by Oxford/AstraZeneca) uses a viral-vector platform: the vector infects cells and delivers genetic material coding for the SARS-CoV-2 spike protein, and the resulting spike-protein expression on infected cells triggers an immune response.
• Covaxin, developed by Bharat Biotech, uses inactivated (whole) virus technology to trigger the immune system into producing antibodies and activating WBCs against SARS-CoV-2.
• Sputnik V, developed by the Gamaleya Institute (Russia), is a viral-vector COVID-19 vaccine similar in design to Covishield; in India it was produced/administered in partnership with the Department of Biotechnology (DBT) under Mission Covid Suraksha, and can also be delivered via a special intradermal system that uses a precise jet stream to penetrate the skin (needing three doses, for those above 12 years).
• iNCOVACC, developed by Bharat Biotech, is the world's first intranasal COVID-19 vaccine, built on an adenovirus-vector platform, offering a needle-free route of administration.
• The Pneumococcal vaccine provides protection against Streptococcus pneumoniae infection and has been included under India's Universal Immunisation Programme, using conjugate-vaccine technology to protect infants.
• The BCG (Bacillus Calmette-Guerin) vaccine, first used in 1921, protects against the severe form of tuberculosis in children (TB is caused by Mycobacterium bovis/tuberculosis, transmitted via the respiratory pathway); it is also used against leprosy and Buruli ulcer, and as an immunotherapy for bladder cancer and malignant melanoma. India accounts for about 27% of the global TB disease burden.
• Toxoid vaccines use a weakened, inactivated form of a harmful bacterial toxin to train the immune system to recognise and fight the disease, e.g. Diphtheria toxoid vaccine and Tetanus toxoid vaccine; active tetanus vaccination (tetanus toxoid) differs from passive vaccination (tetanus immunoglobulin), which offers no lasting immunity but gives immediate help, typically for injury cases with uncertain vaccination history.
• The IPV-vs-OPV distinction (IPV: killed virus, injectable, no local immunity, costlier, no cold-chain; OPV: live attenuated, oral, both humoral and intestinal immunity, cheaper, effective in epidemics, needs sub-zero storage) underpins the global strategy for polio eradication and the shift between vaccine types in endgame phases.
• Cervavac (India's first indigenous quadrivalent HPV vaccine, developed by the Serum Institute of India) supports WHO's cervical cancer elimination strategy targeting 90% HPV vaccination of girls by age 15, 70% screening of women by ages 35 and 45, and 90% treatment of pre-cancer/invasive cancer, by 2030.
• Havisure, India's first indigenous Hepatitis A vaccine, was developed by Indian Immunologicals Ltd, a subsidiary of the National Dairy Development Board (NDDB).
• The experimental inverse vaccine approach exploits the liver's natural immune-tolerance mechanism — pairing a target antigen with a molecule resembling debris from old cells tricks the immune system into not attacking that antigen — offering a potential strategy against autoimmune conditions rather than infections.